Kawamura Kota, Murata Shizumasa, Kitano Yoji, Mera Yoshimasa, Iwahashi Hiroki, Shitahodo Toshiya, Inoue Shingo, Kadono Aozora, Yamada Hiroshi
Department of Orthopedic Surgery, Shingu Municipal Medical Center, 18-7 Hachibuse, Shingu City, Wakayama, 647-0072, Japan.
Department of Orthopaedic Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8510, Japan.
Osteoporos Int. 2025 Mar;36(3):447-454. doi: 10.1007/s00198-025-07404-5. Epub 2025 Jan 28.
Metaphyseal comminution in distal radius fracture (DRF) cases might indicate severe osteoporosis. The patients with DRFs and metaphyseal comminution showed 5.2-fold increased secondary fractures compared with those receiving combination osteoporosis therapy. High-risk DRF patients require aggressive osteoporosis management and fracture risk stratification.
Distal radius fractures (DRFs) are common in patients with osteoporosis and associated with increased risks for subsequent fractures. Metaphyseal comminution in patients with DRFs may indicate severe osteoporosis and heightened bone fragility. However, its relationship with the risk of secondary fragility fractures remains unclear. This study aimed to evaluate the incidence of secondary fractures in patients with DRFs involving metaphyseal comminution and assess the effectiveness of osteoporosis treatment in reducing this risk.
In this retrospective cohort study, 134 patients aged ≥ 50 years underwent DRF surgery at a single institution from July 2018 to December 2022. The patients were allocated into groups by the presence (n = 45) or absence (n = 89) of metaphyseal comminution. The primary outcome was secondary fracture incidence. A multivariate Cox model was used, adjusting for age, sex, body mass index, bone mineral density, osteoporosis treatment type, and dementia.
Secondary fractures were significantly more frequent in the comminution group (17.8%) than in the non-comminution group (3.4%) (p = 0.004). Metaphyseal comminution was associated with 5.2-fold increased secondary fracture risk (hazards ratio: 5.2, 95% confidence interval: 1.4-10.7, p = 0.004). The patients administered combination therapy (active vitamin D plus bisphosphonates or anabolic agents) had notably lower secondary fracture rate than did those receiving vitamin D alone (5.6% vs. 15.4%, p = 0.046).
Metaphyseal comminution in patient with DRFs significantly elevated secondary fracture risk; combination osteoporosis therapy might mitigate this risk. These findings underscore the need for robust osteoporosis management in high-risk patients, suggesting metaphyseal comminution should be crucial for fracture risk stratification.
桡骨远端骨折(DRF)病例中的干骺端粉碎可能提示严重骨质疏松。与接受联合骨质疏松治疗的患者相比,患有DRF且伴有干骺端粉碎的患者继发性骨折增加了5.2倍。高危DRF患者需要积极的骨质疏松管理和骨折风险分层。
桡骨远端骨折(DRF)在骨质疏松患者中很常见,且与后续骨折风险增加相关。DRF患者的干骺端粉碎可能提示严重骨质疏松和更高的骨脆性。然而,其与继发性脆性骨折风险的关系仍不清楚。本研究旨在评估伴有干骺端粉碎的DRF患者继发性骨折的发生率,并评估骨质疏松治疗在降低该风险方面的有效性。
在这项回顾性队列研究中,2018年7月至2022年12月期间,134名年龄≥50岁的患者在单一机构接受了DRF手术。根据是否存在干骺端粉碎将患者分为两组(存在干骺端粉碎组,n = 45;不存在干骺端粉碎组,n = 89)。主要结局是继发性骨折发生率。使用多变量Cox模型,并对年龄、性别、体重指数、骨密度、骨质疏松治疗类型和痴呆进行了校正。
粉碎组继发性骨折的发生率(17.8%)显著高于非粉碎组(3.4%)(p = 0.004)。干骺端粉碎与继发性骨折风险增加5.2倍相关(风险比:5.2,95%置信区间:1.4 - 10.7,p = 0.004)。接受联合治疗(活性维生素D加双膦酸盐或合成代谢药物)的患者继发性骨折率明显低于仅接受维生素D治疗的患者(5.6%对15.4%,p = 0.046)。
DRF患者的干骺端粉碎显著增加了继发性骨折风险;联合骨质疏松治疗可能会降低这种风险。这些发现强调了对高危患者进行强有力的骨质疏松管理的必要性,表明干骺端粉碎对于骨折风险分层至关重要。